Skip to content

Study · Randomized controlled trial · n = 113 · 2009

14 results

Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.

Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, De Marinis L, Klibanski A

Journal of endocrinological investigation4 Dec 2009Cited by 50 (Europe PMC)

PMID20009494 (opens in a new tab)DOI10.1007/bf03345774 (opens in a new tab)PepBankPUB-20009494
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acromegaly, IGF-I normalized in 51% with pegvisomant versus 34% with octreotide LAR (p=0.09, not significant).

    In plain wordsIn acromegaly, IGF-I normalization was numerically higher with pegvisomant than octreotide, without statistical significance.

    Peptide
    Pegvisomant
    Outcome
    IncreaseIGF-I normalization
    Study

    n = 113

    Comparator
    Octreotide LAR
    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    IGF-I normalization rate at week 52
    51%
    pegvisomant
    IGF-I normalization rate at week 52
    34%
    octreotide LAR
    Between-group p-value
    0.09 p
    pegvisomant versus octreotide LAR

    Source sentences

    Summary
    IGF-I normalized in 51% of pegvisomant patients and 34% treated with octreotide LAR (p=0.09, ns).
    3 context sentences
    Summary · context
    The primary endpoint was IGF-I normalization at week 52.
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acromegaly, IGF-I normalized in 34% with octreotide LAR versus 51% with pegvisomant (p=0.09, not significant).

    In plain wordsIn acromegaly, IGF-I normalization was numerically lower with octreotide than pegvisomant, without statistical significance.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-I normalization
    Study

    n = 113

    Comparator
    Pegvisomant
    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    IGF-I normalization rate at week 52
    34%
    octreotide LAR
    IGF-I normalization rate at week 52
    51%
    pegvisomant
    Between-group p-value
    0.09 p
    octreotide LAR versus pegvisomant

    Source sentences

    Summary
    IGF-I normalized in 51% of pegvisomant patients and 34% treated with octreotide LAR (p=0.09, ns).
    3 context sentences
    Summary · context
    The primary endpoint was IGF-I normalization at week 52.
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acromegaly, mean tumor-volume changes were similar with pegvisomant and octreotide LAR.

    In plain wordsIn acromegaly, tumor-volume changes were similar with pegvisomant and octreotide.

    Peptide
    Pegvisomant
    Outcome
    Direction not reportedTumor volume change
    Study

    n = 113

    Comparator
    Octreotide LAR
    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mean change in tumor volume during treatment was similar between groups.
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In acromegaly, mean tumor-volume changes were similar with octreotide LAR and pegvisomant.

    In plain wordsIn acromegaly, tumor-volume changes were similar with octreotide and pegvisomant.

    Peptide
    Octreotide
    Outcome
    Direction not reportedTumor volume change
    Study

    n = 113

    Comparator
    Pegvisomant
    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mean change in tumor volume during treatment was similar between groups.
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In acromegaly with baseline IGF-I at least twice normal, pegvisomant produced higher normalization rates than octreotide LAR (p=0.05).

    In plain wordsIn acromegaly with high initial IGF-I, normalization was more frequent with pegvisomant than octreotide.

    Peptide
    Pegvisomant
    Outcome
    IncreaseIGF-I normalization with high baseline IGF-I
    Study

    n: not reported in source

    Comparator
    Octreotide LAR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Between-group p-value
    0.05 p
    baseline IGF-I at least 2x ULN, pegvisomant versus octreotide LAR

    Source sentences

    Summary
    Patients with baseline IGF-I > or = 2x upper limit of normal had a higher rate of IGF-I normalization with pegvisomant vs octreotide LAR (p=0.05).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In acromegaly with baseline IGF-I at least twice normal, octreotide LAR produced lower normalization rates than pegvisomant (p=0.05).

    In plain wordsIn acromegaly with high initial IGF-I, normalization was less frequent with octreotide than pegvisomant.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-I normalization with high baseline IGF-I
    Study

    n: not reported in source

    Comparator
    Pegvisomant
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Between-group p-value
    0.05 p
    baseline IGF-I at least 2x ULN, octreotide LAR versus pegvisomant

    Source sentences

    Summary
    Patients with baseline IGF-I > or = 2x upper limit of normal had a higher rate of IGF-I normalization with pegvisomant vs octreotide LAR (p=0.05).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In diabetic acromegaly patients, fasting glucose decreased with pegvisomant and increased with octreotide at week 52 (between-group p=0.005).

    In plain wordsIn diabetic acromegaly patients, fasting glucose changed more favorably with pegvisomant than octreotide.

    Peptide
    Pegvisomant
    Outcome
    DecreaseFasting glucose in diabetic patients
    Study

    n: not reported in source

    Comparator
    Octreotide LAR
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Between-group p-value for fasting glucose at week 52
    0.005 p
    diabetic patients, pegvisomant versus octreotide LAR

    Source sentences

    Summary
    Mean fasting glucose decreased in diabetic and non-diabetic patients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In non-diabetic acromegaly patients, fasting glucose decreased with pegvisomant and increased with octreotide at week 52 (between-group p=0.003).

    In plain wordsIn non-diabetic acromegaly patients, fasting glucose changed more favorably with pegvisomant than octreotide.

    Peptide
    Pegvisomant
    Outcome
    DecreaseFasting glucose in non-diabetic patients
    Study

    n: not reported in source

    Comparator
    Octreotide LAR
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Between-group p-value for fasting glucose at week 52
    0.003 p
    non-diabetic patients, pegvisomant versus octreotide LAR

    Source sentences

    Summary
    Mean fasting glucose decreased in diabetic and non-diabetic patients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In diabetic acromegaly patients, fasting glucose increased with octreotide and decreased with pegvisomant at week 52 (between-group p=0.005).

    In plain wordsIn diabetic acromegaly patients, fasting glucose changed less favorably with octreotide than pegvisomant.

    Peptide
    Octreotide
    Outcome
    IncreaseFasting glucose in diabetic patients
    Study

    n: not reported in source

    Comparator
    Pegvisomant
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Between-group p-value for fasting glucose at week 52
    0.005 p
    diabetic patients, octreotide LAR versus pegvisomant

    Source sentences

    Summary
    Mean fasting glucose decreased in diabetic and non-diabetic patients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In non-diabetic acromegaly patients, fasting glucose increased with octreotide and decreased with pegvisomant at week 52 (between-group p=0.003).

    In plain wordsIn non-diabetic acromegaly patients, fasting glucose changed less favorably with octreotide than pegvisomant.

    Peptide
    Octreotide
    Outcome
    IncreaseFasting glucose in non-diabetic patients
    Study

    n: not reported in source

    Comparator
    Pegvisomant
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Between-group p-value for fasting glucose at week 52
    0.003 p
    non-diabetic patients, octreotide LAR versus pegvisomant

    Source sentences

    Summary
    Mean fasting glucose decreased in diabetic and non-diabetic patients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  11. 11HumanNon-randomized trialSafety outcome

    In acromegaly, treatment-related adverse events were mild-to-moderate with pegvisomant and octreotide LAR.

    In plain wordsIn acromegaly, treatment-related adverse events were mild-to-moderate with pegvisomant and octreotide.

    Peptide
    Pegvisomant
    Outcome
    Not applicableTreatment-related adverse-event severity
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment-related adverse events were mild-to-moderate in both groups.
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  12. 12HumanNon-randomized trialSafety outcome

    In acromegaly, treatment-related adverse events were mild-to-moderate with octreotide LAR and pegvisomant.

    In plain wordsIn acromegaly, treatment-related adverse events were mild-to-moderate with octreotide and pegvisomant.

    Peptide
    Octreotide
    Outcome
    Not applicableTreatment-related adverse-event severity
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment-related adverse events were mild-to-moderate in both groups.
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  13. 13HumanObservational studyOther

    Among acromegaly patients without normalized IGF-I, 71% on pegvisomant versus 16% on octreotide received less than 30 mg.

    In plain wordsAmong patients without normalized IGF-I, low study-drug doses were more frequent with pegvisomant than octreotide.

    Peptide
    Pegvisomant
    Outcome
    IncreaseDose below 30 mg among non-normalizers
    Study

    n: not reported in source

    Comparator
    Octreotide LAR non-normalizers
    Outcome group
    Dosing · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Patients receiving less than 30 mg of study drug among non-normalizers
    71%
    pegvisomant
    Patients receiving less than 30 mg of study drug among non-normalizers
    16%
    octreotide LAR

    Source sentences

    Summary
    Among the patients who did not achieve a normalized IGF-I, pegvisomant-treated patients were more likely to be receiving < 30 mg of study drug (71% vs 16%).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.
  14. 14HumanObservational studyOther

    Among acromegaly patients without normalized IGF-I, 16% on octreotide versus 71% on pegvisomant received less than 30 mg.

    In plain wordsAmong patients without normalized IGF-I, low study-drug doses were less frequent with octreotide than pegvisomant.

    Peptide
    Octreotide
    Outcome
    DecreaseDose below 30 mg among non-normalizers
    Study

    n: not reported in source

    Comparator
    Pegvisomant non-normalizers
    Outcome group
    Dosing · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Patients receiving less than 30 mg of study drug among non-normalizers
    16%
    octreotide LAR
    Patients receiving less than 30 mg of study drug among non-normalizers
    71%
    pegvisomant

    Source sentences

    Summary
    Among the patients who did not achieve a normalized IGF-I, pegvisomant-treated patients were more likely to be receiving < 30 mg of study drug (71% vs 16%).
    2 context sentences
    Summary · context
    The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study.
    Summary · context
    Fifty-six patients received pegvisomant and 57 received octreotide LAR.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.